Overall, our findings were in keeping with the hypothesis that reduced levels of AT impair FXa generation and that therapeutic FX or pd-FVIIa/FX could enhance FVIIa/TF-induced activation of FX and increase coagulation potential in the AT-reduced plasma of people with hemophilia. The gene discussed is F10; the disease is hemophilia.